Deep Track Capital
Superinvestor profile · Rank #68 by reported 13F value (2026 Q2 filers) · CIK 0001856083 · All profiles
Founded 2020Greenwich, Connecticut, USLife sciences and biotechnology long/short equity, including activist positionsKey person: David Kroin
Reported 13F value
$6.9B
Period 2026-06-30 · Filed 2026-08-14
Positions
67
Top 10 = 39.6% of value
Clone CAGR (full window)
+24.6%
2022-02-14 → 2026-10-02 · cumulative +177%
SPY CAGR (same window)
+14.4%
Cumulative +87%
Max drawdown (monthly)
-34%
Month-end values, approximate
Latest-quarter activity
19 new · 15 exited
22 increased · 15 decreased
Hypothetical clone — not this fund's returns. The performance on this page replicates only the long U.S. equity positions disclosed on this manager's Form 13F filings, rebalanced on filing dates at disclosed weights with dividend-adjusted prices. It excludes shorts, bonds, cash, non-U.S. listings, private holdings, leverage and fees. Treat it as a measure of how the disclosed stock picks performed, never as the fund's track record. Evidence: filing-by-filing dossier (PDF) · Methodology (PDF)
Clone performance
| Window | Clone CAGR | Note |
|---|---|---|
| Full window (2022-02-14 → 2026-10-02, 19 filings) | +24.60% | Cumulative +176.8% vs SPY +86.8% |
| Trailing 10Y | — | |
| Trailing 5Y | — | |
| Trailing 3Y | +35.00% | |
| Trailing 1Y | +50.89% |
Top holdings — 2026 Q2 filing
| Ticker | Company | Weight | Reported value |
|---|---|---|---|
| GH | Guardant Health Inc | 7.41% | $509M |
| IMVT | Immunovant Inc | 5.24% | $360M |
| GPCR | Structure Therapeutics Inc | 3.70% | $254M |
| PCVX | Vaxcyte Inc | 3.64% | $250M |
| ALNY | Alnylam Pharmaceuticals Inc | 3.61% | $248M |
| MANE | Veradermics Inc | 3.58% | $246M |
| TARS | Tarsus Pharmaceuticals Inc | 3.36% | $231M |
| Nuvalent Inc | 3.21% | $220M | |
| ALKS | Alkermes Plc | 3.05% | $210M |
| OCUL | Ocular Therapeutix Inc | 2.81% | $193M |
As reported on the 2026-06-30 Form 13F (filed 2026-08-14). Full holdings and quarter changes: holdings page.
Filing history in this profile
Every clone input traces to one of these SEC filings. 83.8% of the latest filing's reported value is covered by our price history; the remainder is mostly non-U.S. listings, recent IPOs or delisted names and is excluded from the clone.
| Quarter | SEC accession no. | Filed | Disclosed CUSIPs |
|---|---|---|---|
| 2026Q2 | 0001856083-26-000004 | 2026-08-14 | 66 |
| 2026Q1 | 0001856083-26-000003 | 2026-05-15 | 62 |
| 2025Q4 | 0001856083-26-000001 | 2026-02-13 | 53 |
| 2025Q3 | 0001856083-25-000006 | 2025-11-14 | 56 |
| 2025Q2 | 0001856083-25-000004 | 2025-08-14 | 65 |
| 2025Q1 | 0001856083-25-000002 | 2025-05-15 | 69 |
| 2024Q4 | 0001856083-25-000001 | 2025-02-14 | 61 |
| 2024Q3 | 0001856083-24-000007 | 2024-11-14 | 69 |
| 2024Q2 | 0001856083-24-000003 | 2024-08-14 | 67 |
| 2024Q1 | 0001856083-24-000002 | 2024-05-15 | 65 |
| 2023Q4 | 0001856083-24-000001 | 2024-02-14 | 57 |
| 2023Q3 | 0001856083-23-000005 | 2023-11-14 | 62 |
| 2023Q2 | 0001856083-23-000004 | 2023-09-06 | 53 |
| 2023Q1 | 0001856083-23-000002 | 2023-05-15 | 54 |
| 2022Q4 | 0001856083-23-000001 | 2023-02-14 | 57 |
| 2022Q3 | 0001856083-22-000012 | 2022-11-14 | 60 |
| 2022Q2 | 0001856083-22-000011 | 2022-08-12 | 49 |
| 2022Q1 | 0001856083-22-000010 | 2022-05-16 | 49 |
| 2021Q4 | 0001856083-22-000007 | 2022-02-14 | 49 |
Background (founded / HQ / style) source: https://www.owler.com/company/deeptrackcapital — Founded by David E. Kroin, who previously co-founded Great Point Partners; Reuters reported it launched a proxy fight at Dynavax Technologies in 2025.